Cargando…
Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
OBJECTIVE: To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson’s disease (PD) compared with healthy controls (HC). METHODS: Parkinson’s Progression Markers Initiative (PPMI) is a longitudin...
Autores principales: | Simuni, Tanya, Caspell-Garcia, Chelsea, Coffey, Christopher S, Weintraub, Daniel, Mollenhauer, Brit, Lasch, Shirley, Tanner, Caroline M, Jennings, Danna, Kieburtz, Karl, Chahine, Lana M, Marek, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732865/ https://www.ncbi.nlm.nih.gov/pubmed/28986467 http://dx.doi.org/10.1136/jnnp-2017-316213 |
Ejemplares similares
-
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018) -
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022) -
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023) -
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016) -
Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)